Sfoglia per Autore RIPA, MARCO
Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient
2013-01-01 Ripa, Marco; Chiappetta, Stefania; Nozza, Silvia
Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection
2014-01-01 Silvia, Nozza; Pignataro, Angela R.; Laura, Galli; Ripa, Marco; Enzo, Boeri; Stefania, Chiappetta; Andrea, Galli; Filippo, Canducci; Michela, Sampaolo; Clementi, Massimo; Adriano, Lazzarin; Giuseppe, Tambussi; Nozza, Silvia
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine
2014-01-01 Nozza, S; Galli, L; Bigoloni, A; Gianotti, N; Spagnuolo, Vincenzo; Carbone, A; Chiappetta, S; Ripa, M; Tambussi, G; Lazzarin, A; Castagna, Antonella
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection
2014-01-01 Nozza, Silvia; Bigoloni, Alba; Calcagno, Andrea; Galli, Laura; Pignataro Angela, Rosa; D'Avolio, Antonio; Carbone, Alessia; Ripa, Marco; Bonora, Stefano; Lazzarin, Adriano; Castagna, Antonella
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area
2015-01-01 Gaiera, G; Chiappetta, S; Carbone, A; Ripa, M; Bigoloni, A; Sala, A; Pozzi, T; Bertocchi, I; Galli, L; Ceserani, N; Poli, A; Castagna, A; Lazzarin, A
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets
2015-01-01 Pogliaghi, Manuela; Ripa, Marco; Pensieroso, Simone; Tolazzi, Monica; Chiappetta, Stefania; Nozza, Silvia; Lazzarin, Adriano; Tambussi, Giuseppe; Scarlatti, Gabriella
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study
2015-01-01 Nozza, S.; Galli, L.; Antinori, A.; Chiappetta, S.; Mazzotta, F.; Zaccarelli, M.; Ottou, S.; De Battista, D.; Pogliaghi, M.; Di Pietro, M.; Malnati, M.; Ripa, M.; Bonora, S.; Lazzarin, A.
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients
2015-01-01 Ceresola Elisa, Rita; Nozza, Silvia; Sampaolo, Michela; Pignataro Angela, Rosa; Saita, Diego; Ferrarese, Roberto; Ripa, Marco; Deng, Wenjie; Mullins James, I.; Boeri, Enzo; Tambussi, Giuseppe; Toniolo, Antonio; Lazzarin, Adriano; Clementi, Massimo; Canducci, Filippo
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial
2015-01-01 Ripa, M.; Pogliaghi, M.; Chiappetta, S.; Galli, L.; Pensieroso, S.; Cavarelli, M.; Scarlatti, G.; De Biasi, S.; Cossarizza, A.; De Battista, D.; Malnati, M.; Lazzarin, A.; Nozza, S.; Tambussi, G.
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study
2016-01-01 Nozza, Silvia; Pignataro, Angela Rosa; Galli, Laura; Svicher, Valentina; Alteri, Claudia; Boeri, Enzo; Ripa, Marco; Castagna, Antonella; Sampaolo, Michela; Clementi, Massimo; Perno, Carlo Federico; Lazzarin, Adriano
Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART
2016-01-01 Chiappetta, S.; Ripa, M.; Galli, L.; Razzari, C.; Longo, V.; Galli, A.; Faioni, E. M.; Nozza, S.; Lazzarin, A.; Tambussi, G.
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up
2016-01-01 Ripa, Marco; Pogliaghi, Manuela; Chiappetta, Stefania; Nozza, Silvia; Soria, Alessandro; Coppalini, Giacomo; Rovelli, Cristina; Tambussi, Giuseppe
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir
2016-01-01 Gianotti, Nicola; Galli, Laura; Poli, Andrea; Salpietro, Stefania; Nozza, Silvia; Carbone, Alessia; Merli, Marco; Ripa, Marco; Lazzarin, Adriano; Castagna, Antonella
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response
2017-01-01 Nozza, Silvia; Poli, Andrea; Ripa, Marco; Galli, Laura; Chiappetta, Stefania; Spagnuolo, Vincenzo; Rovelli, Cristina; Lazzarin, Adriano; Castagna, Antonella; Tambussi, Giuseppe
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection
2017-01-01 Nozza, Silvia; Poli, Andrea; Ripa, Marco; Galli, Laura; Chiappetta, Stefania; Spagnuolo, Vincenzo; Rovelli, Cristina; Lazzarin, Adriano; Castagna, Antonella; Tambussi, Giuseppe
Immunosenescence and hurdles in the clinical management of older HIV-patients
2017-01-01 Ripa, Marco; Chiappetta, Stefania; Tambussi, Giuseppe
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: A propensity score-adjusted and matched analysis
2017-01-01 Ripa, Marco; Rodríguez-Núñez, Olga; Cardozo, Celia; Naharro-Abellán, Antonio; Almela, Manel; Marco, Francesc; Morata, Laura; De La Calle, Cristina; Del Rio, Ana; Garcia-Vidal, Carolina; Ortega, María Del Mar; Guerrero-León, María De Los Angeles; Feher, Csaba; Torres, Berta; Puerta-Alcalde, Pedro; Mensa, Josep; Soriano, Alex; Martínez, José Antonio
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
2017-01-01 Gianotti, Nicola; Poli, Andrea; Nozza, Silvia; Galli, Laura; Galizzi, Nadia; Ripa, Marco; Merli, Marco; Carbone, Alessia; Spagnuolo, Vincenzo; Lazzarin, Adriano; Castagna, Antonella
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen
2018-01-01 Gianotti, Nicola; Galli, Laura; Galizzi, Nadia; Ripa, Marco; Andolina, Andrea; Nozza, Silvia; Spagnuolo, Vincenzo; Poli, Andrea; Lazzarin, Adriano; Castagna, Antonella
Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa
2018-01-01 Rodríguez-Núñez, Olga; Ripa, Marco; Morata, Laura; de la Calle, Cristina; Cardozo, Celia; Fehér, Csaba; Pellicé, Martina; Valcárcel, Andrea; Puerta-Alcalde, Pedro; Marco, Francesc; García-Vidal, Carolina; del Río, Ana; Soriano, Alex; Martínez-Martínez, Jose Antonio
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient | 1-gen-2013 | Ripa, Marco; Chiappetta, Stefania; Nozza, Silvia | |
| Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection | 1-gen-2014 | Silvia, Nozza; Pignataro, Angela R.; Laura, Galli; Ripa, Marco; Enzo, Boeri; Stefania, Chiappetta; Andrea, Galli; Filippo, Canducci; Michela, Sampaolo; Clementi, Massimo; Adriano, Lazzarin; Giuseppe, Tambussi; Nozza, Silvia | |
| Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine | 1-gen-2014 | Nozza, S; Galli, L; Bigoloni, A; Gianotti, N; Spagnuolo, Vincenzo; Carbone, A; Chiappetta, S; Ripa, M; Tambussi, G; Lazzarin, A; Castagna, Antonella | |
| Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection | 1-gen-2014 | Nozza, Silvia; Bigoloni, Alba; Calcagno, Andrea; Galli, Laura; Pignataro Angela, Rosa; D'Avolio, Antonio; Carbone, Alessia; Ripa, Marco; Bonora, Stefano; Lazzarin, Adriano; Castagna, Antonella | |
| Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area | 1-gen-2015 | Gaiera, G; Chiappetta, S; Carbone, A; Ripa, M; Bigoloni, A; Sala, A; Pozzi, T; Bertocchi, I; Galli, L; Ceserani, N; Poli, A; Castagna, A; Lazzarin, A | |
| Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets | 1-gen-2015 | Pogliaghi, Manuela; Ripa, Marco; Pensieroso, Simone; Tolazzi, Monica; Chiappetta, Stefania; Nozza, Silvia; Lazzarin, Adriano; Tambussi, Giuseppe; Scarlatti, Gabriella | |
| Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study | 1-gen-2015 | Nozza, S.; Galli, L.; Antinori, A.; Chiappetta, S.; Mazzotta, F.; Zaccarelli, M.; Ottou, S.; De Battista, D.; Pogliaghi, M.; Di Pietro, M.; Malnati, M.; Ripa, M.; Bonora, S.; Lazzarin, A. | |
| Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients | 1-gen-2015 | Ceresola Elisa, Rita; Nozza, Silvia; Sampaolo, Michela; Pignataro Angela, Rosa; Saita, Diego; Ferrarese, Roberto; Ripa, Marco; Deng, Wenjie; Mullins James, I.; Boeri, Enzo; Tambussi, Giuseppe; Toniolo, Antonio; Lazzarin, Adriano; Clementi, Massimo; Canducci, Filippo | |
| Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial | 1-gen-2015 | Ripa, M.; Pogliaghi, M.; Chiappetta, S.; Galli, L.; Pensieroso, S.; Cavarelli, M.; Scarlatti, G.; De Biasi, S.; Cossarizza, A.; De Battista, D.; Malnati, M.; Lazzarin, A.; Nozza, S.; Tambussi, G. | |
| 48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study | 1-gen-2016 | Nozza, Silvia; Pignataro, Angela Rosa; Galli, Laura; Svicher, Valentina; Alteri, Claudia; Boeri, Enzo; Ripa, Marco; Castagna, Antonella; Sampaolo, Michela; Clementi, Massimo; Perno, Carlo Federico; Lazzarin, Adriano | |
| Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART | 1-gen-2016 | Chiappetta, S.; Ripa, M.; Galli, L.; Razzari, C.; Longo, V.; Galli, A.; Faioni, E. M.; Nozza, S.; Lazzarin, A.; Tambussi, G. | |
| Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up | 1-gen-2016 | Ripa, Marco; Pogliaghi, Manuela; Chiappetta, Stefania; Nozza, Silvia; Soria, Alessandro; Coppalini, Giacomo; Rovelli, Cristina; Tambussi, Giuseppe | |
| Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir | 1-gen-2016 | Gianotti, Nicola; Galli, Laura; Poli, Andrea; Salpietro, Stefania; Nozza, Silvia; Carbone, Alessia; Merli, Marco; Ripa, Marco; Lazzarin, Adriano; Castagna, Antonella | |
| Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response | 1-gen-2017 | Nozza, Silvia; Poli, Andrea; Ripa, Marco; Galli, Laura; Chiappetta, Stefania; Spagnuolo, Vincenzo; Rovelli, Cristina; Lazzarin, Adriano; Castagna, Antonella; Tambussi, Giuseppe | |
| Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection | 1-gen-2017 | Nozza, Silvia; Poli, Andrea; Ripa, Marco; Galli, Laura; Chiappetta, Stefania; Spagnuolo, Vincenzo; Rovelli, Cristina; Lazzarin, Adriano; Castagna, Antonella; Tambussi, Giuseppe | |
| Immunosenescence and hurdles in the clinical management of older HIV-patients | 1-gen-2017 | Ripa, Marco; Chiappetta, Stefania; Tambussi, Giuseppe | |
| Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: A propensity score-adjusted and matched analysis | 1-gen-2017 | Ripa, Marco; Rodríguez-Núñez, Olga; Cardozo, Celia; Naharro-Abellán, Antonio; Almela, Manel; Marco, Francesc; Morata, Laura; De La Calle, Cristina; Del Rio, Ana; Garcia-Vidal, Carolina; Ortega, María Del Mar; Guerrero-León, María De Los Angeles; Feher, Csaba; Torres, Berta; Puerta-Alcalde, Pedro; Mensa, Josep; Soriano, Alex; Martínez, José Antonio | |
| Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients | 1-gen-2017 | Gianotti, Nicola; Poli, Andrea; Nozza, Silvia; Galli, Laura; Galizzi, Nadia; Ripa, Marco; Merli, Marco; Carbone, Alessia; Spagnuolo, Vincenzo; Lazzarin, Adriano; Castagna, Antonella | |
| Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen | 1-gen-2018 | Gianotti, Nicola; Galli, Laura; Galizzi, Nadia; Ripa, Marco; Andolina, Andrea; Nozza, Silvia; Spagnuolo, Vincenzo; Poli, Andrea; Lazzarin, Adriano; Castagna, Antonella | |
| Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa | 1-gen-2018 | Rodríguez-Núñez, Olga; Ripa, Marco; Morata, Laura; de la Calle, Cristina; Cardozo, Celia; Fehér, Csaba; Pellicé, Martina; Valcárcel, Andrea; Puerta-Alcalde, Pedro; Marco, Francesc; García-Vidal, Carolina; del Río, Ana; Soriano, Alex; Martínez-Martínez, Jose Antonio |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile